Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
28,959
Total Claims
$6.2M
Drug Cost
621
Beneficiaries
$9,993
Cost/Patient
Risk Score Breakdown 18/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+608%
Cost per patient vs peers
$9,993 vs $1,411 avg
+116%
Brand preference vs peers
23.0% vs 10.6% avg
🔎 Data Overview
Cost per patient is 608% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 6,547 claims · $4.9M
Generic: 21,912 claims · $1.3M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lipase/Protease/Amylase | 652 | $1.5M |
| Icosapent Ethyl | 1,752 | $786K |
| Diclofenac Epolamine | 666 | $481K |
| Linaclotide | 342 | $219K |
| Cyclosporine | 305 | $207K |
| Omeprazole/Sodium Bicarbonate | 115 | $164K |
| Sitagliptin Phosphate | 180 | $139K |
| Semaglutide | 97 | $122K |
| Tenofovir Alafenamide | 77 | $121K |
| Empagliflozin | 149 | $120K |
| Tenapanor Hcl | 55 | $99K |
| Diclofenac Potassium | 45 | $99K |
| Clemastine Fumarate | 19 | $93K |
| Lactulose | 28 | $89K |
| Dulaglutide | 58 | $87K |
Prescribing Profile
Patient Profile
72
Avg Age
45%
Female
1.02
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data